KZR - Kezar Life Sciences, Inc.
Kezar Life Sciences, Inc. , a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis.
As of May 13, 2026: spot at $23.61, ATM IV 251.9%, max pain $7.50, net GEX -$1.5K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $53.9M
- Beta
- 0.41
- 52-Week Range
- 3.53-7.55
- CEO
- Christopher J. Kirk
- Employees
- 55
- IPO Date
- Jun 21, 2018
- Exchange
- NASDAQ
What KZR Looks Like to Options Traders Today
IV rank of 49.7% sits near the 1-year median, where strategy choice depends on directional conviction and the event calendar rather than vol regime alone; negative net gamma exposure (-$1.5K) means dealers hedge with trend, amplifying realized volatility and accelerating directional moves; the 25-delta skew (0.083) prices calls richer than puts, often reflecting upside speculation or squeeze risk.
What This Page Covers
The KZR overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked KZR overview questions
- What is KZR?
- KZR is the ticker symbol for Kezar Life Sciences, Inc., a listed security. Kezar Life Sciences, Inc. , a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. Listed on NASDAQ. KZR is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the KZR options snapshot look like today?
- As of May 13, 2026, the KZR options snapshot shows spot at $23.61, ATM IV 251.9%, IV rank 49.7%, max pain $7.50, net GEX -$1.5K, expected move 72.22%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are KZR's key statistics?
- Kezar Life Sciences, Inc. (KZR) carries a market capitalization of $53.9M, beta of 0.41 relative to the broader market, 52-week range of 3.53-7.55. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does KZR belong to?
- Kezar Life Sciences, Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare KZR's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the KZR data on this page?
- The options snapshot above is dated May 13, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).